Neoleukin Therapeutics, Inc. Logo

Neoleukin Therapeutics, Inc.

NLTX

(1.5)
Stock Price

3,49 USD

-43.93% ROA

-47.64% ROE

-0.98x PER

Market Cap.

8.199.685,00 USD

14.21% DER

0% Yield

0% NPM

Neoleukin Therapeutics, Inc. Stock Analysis

Neoleukin Therapeutics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Neoleukin Therapeutics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (14%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (2.36x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

4 Net Profit Growth

Throughout the last three years, this company has experienced consistent net profit growth, reflecting a robust financial performance and making it an attractive investment prospect.

5 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

6 ROE

The stock's ROE indicates a negative return (-52.5%) on shareholders' equity, suggesting poor financial performance.

7 ROA

The stock's ROA (-50.39%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Neoleukin Therapeutics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Neoleukin Therapeutics, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Neoleukin Therapeutics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Neoleukin Therapeutics, Inc. Revenue
Year Revenue Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 25.000.000 100%
2019 0 0%
2020 451.000 100%
2021 6.000 -7416.67%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Neoleukin Therapeutics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2012 6.045.395
2013 7.539.179 19.81%
2014 18.079.262 58.3%
2015 15.799.000 -14.43%
2016 28.382.000 44.33%
2017 36.267.000 21.74%
2018 41.789.000 13.21%
2019 4.417.000 -846.09%
2020 24.344.000 81.86%
2021 39.162.000 37.84%
2022 41.129.000 4.78%
2023 2.468.000 -1566.49%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Neoleukin Therapeutics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 1.635.623
2013 1.776.905 7.95%
2014 4.296.447 58.64%
2015 5.541.000 22.46%
2016 9.263.000 40.18%
2017 14.852.000 37.63%
2018 15.835.000 6.21%
2019 18.826.000 15.89%
2020 17.210.000 -9.39%
2021 21.536.000 20.09%
2022 17.968.000 -19.86%
2023 19.808.000 9.29%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Neoleukin Therapeutics, Inc. EBITDA
Year EBITDA Growth
2012 -7.531.650
2013 -9.676.183 22.16%
2014 -24.378.890 60.31%
2015 -21.709.000 -12.3%
2016 -37.069.000 41.44%
2017 -50.160.000 26.1%
2018 -31.506.000 -59.21%
2019 -21.369.000 -47.44%
2020 -47.564.000 55.07%
2021 -60.698.000 21.64%
2022 -56.485.000 -7.46%
2023 -20.752.000 -172.19%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Neoleukin Therapeutics, Inc. Gross Profit
Year Gross Profit Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 25.000.000 100%
2019 0 0%
2020 451.000 100%
2021 6.000 -7416.67%
2022 0 0%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Neoleukin Therapeutics, Inc. Net Profit
Year Net Profit Growth
2012 -12.137.948
2013 -9.299.658 -30.52%
2014 -23.821.276 60.96%
2015 -21.860.000 -8.97%
2016 -37.002.000 40.92%
2017 -50.183.000 26.27%
2018 -31.585.000 -58.88%
2019 -69.435.000 54.51%
2020 -24.956.000 -178.23%
2021 -58.415.000 57.28%
2022 -56.017.000 -4.28%
2023 -18.104.000 -209.42%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Neoleukin Therapeutics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 -2
2013 -1 0%
2014 -3 100%
2015 -2 -100%
2016 -2 0%
2017 -2 50%
2018 -1 -100%
2019 -3 50%
2020 0 0%
2021 -1 100%
2022 -1 0%
2023 -2 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Neoleukin Therapeutics, Inc. Free Cashflow
Year Free Cashflow Growth
2012 -7.238.649
2013 -7.949.755 8.95%
2014 -17.919.455 55.64%
2015 -20.295.000 11.71%
2016 -30.939.000 34.4%
2017 -45.212.000 31.57%
2018 -31.626.000 -42.96%
2019 -16.273.000 -94.35%
2020 -26.794.000 39.27%
2021 -50.821.000 47.28%
2022 -46.717.000 -8.78%
2023 -4.269.000 -994.33%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Neoleukin Therapeutics, Inc. Operating Cashflow
Year Operating Cashflow Growth
2012 -7.232.202
2013 -7.938.014 8.89%
2014 -17.805.565 55.42%
2015 -20.268.000 12.15%
2016 -30.226.000 32.95%
2017 -44.718.000 32.41%
2018 -31.577.000 -41.62%
2019 -15.394.000 -105.13%
2020 -24.575.000 37.36%
2021 -47.558.000 48.33%
2022 -45.607.000 -4.28%
2023 -4.269.000 -968.33%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Neoleukin Therapeutics, Inc. Capital Expenditure
Year Capital Expenditure Growth
2012 6.447
2013 11.741 45.09%
2014 113.890 89.69%
2015 27.000 -321.81%
2016 713.000 96.21%
2017 494.000 -44.33%
2018 49.000 -908.16%
2019 879.000 94.43%
2020 2.219.000 60.39%
2021 3.263.000 32%
2022 1.110.000 -193.96%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Neoleukin Therapeutics, Inc. Equity
Year Equity Growth
2012 -51.101.207
2013 10.762.588 574.8%
2014 36.147.298 70.23%
2015 108.420.000 66.66%
2016 144.664.000 25.05%
2017 98.887.000 -46.29%
2018 72.672.000 -36.07%
2019 141.687.000 48.71%
2020 191.216.000 25.9%
2021 142.864.000 -33.84%
2022 94.331.000 -51.45%
2023 75.235.000 -25.38%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Neoleukin Therapeutics, Inc. Assets
Year Assets Growth
2012 2.341.990
2013 15.649.106 85.03%
2014 41.422.947 62.22%
2015 113.343.000 63.45%
2016 154.380.000 26.58%
2017 110.329.000 -39.93%
2018 77.618.000 -42.14%
2019 147.023.000 47.21%
2020 210.519.000 30.16%
2021 163.263.000 -28.94%
2022 115.948.000 -40.81%
2023 89.586.000 -29.43%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Neoleukin Therapeutics, Inc. Liabilities
Year Liabilities Growth
2012 53.443.197
2013 4.886.518 -993.69%
2014 5.275.649 7.38%
2015 4.923.000 -7.16%
2016 9.716.000 49.33%
2017 11.442.000 15.08%
2018 4.946.000 -131.34%
2019 5.336.000 7.31%
2020 19.303.000 72.36%
2021 20.399.000 5.37%
2022 21.617.000 5.63%
2023 14.351.000 -50.63%

Neoleukin Therapeutics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-3.55
Price to Earning Ratio
-0.98x
Price To Sales Ratio
0x
POCF Ratio
-1.2
PFCF Ratio
-0.25
Price to Book Ratio
0.51
EV to Sales
0
EV Over EBITDA
0.22
EV to Operating CashFlow
0.2
EV to FreeCashFlow
0.19
Earnings Yield
-1.02
FreeCashFlow Yield
-4.02
Market Cap
0,01 Bil.
Enterprise Value
-0,01 Bil.
Graham Number
23.25
Graham NetNet
5.78

Income Statement Metrics

Net Income per Share
-3.55
Income Quality
0.94
ROE
-0.48
Return On Assets
-0.44
Return On Capital Employed
-0.45
Net Income per EBT
1.15
EBT Per Ebit
0.9
Ebit per Revenue
0
Effective Tax Rate
-0.15

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-2.91
Free CashFlow per Share
-2.97
Capex to Operating CashFlow
0.02
Capex to Revenue
0
Capex to Depreciation
-0.33
Return on Invested Capital
-0.51
Return on Tangible Assets
-0.44
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0.06

Balance Sheet

Cash per Share
7,07
Book Value per Share
6,78
Tangible Book Value per Share
6.78
Shareholders Equity per Share
6.78
Interest Debt per Share
0.95
Debt to Equity
0.14
Debt to Assets
0.12
Net Debt to EBITDA
0.5
Current Ratio
15.33
Tangible Asset Value
0,08 Bil.
Net Current Asset Value
0,07 Bil.
Invested Capital
0.14
Working Capital
0,07 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
1.3

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Neoleukin Therapeutics, Inc. Dividends
Year Dividends Growth

Neoleukin Therapeutics, Inc. Profile

About Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

CEO
Ms. Donna M. Cochener-Metcalfe
Employee
7
Address
188 East Blaine Street
Seattle, 98102

Neoleukin Therapeutics, Inc. Executives & BODs

Neoleukin Therapeutics, Inc. Executives & BODs
# Name Age
1 Dr. Bill Arthur
Vice President & Head of Research
70
2 Mr. Umut Ulge
Vice President of Clinical Devel.
70
3 Dr. Priti Patel M.D., M.S.
Chief Medical Officer
70
4 Dr. Carl Walkey Ph.D.
Senior Vice President of Corporation Devel.
70
5 Mr. Kamran Alam
Senior Strategic Advisor
70
6 Dr. David Baker
Co-founder & Member of Scientific Advisory Board
70
7 Dr. Jonathan G. Drachman M.D.
Chief Executive Officer, Pres, Principal Financial Officer & Director
70
8 Dr. David Baker M.D., Ph.D.
Co-Founder
70
9 Mr. Sean Michael Smith
Interim Chief Financial Officer
70

Neoleukin Therapeutics, Inc. Competitors